Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Drug Discovery And Clinic S R L is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner, AULAKH, CHARANJIT, who is the busiest examiner for the portfolio with 1 pending office action. All current activity is located within 1 distinct art unit, showing a high degree of technical concentration.
Because there is only 1 distinct examiner involved, the company can tailor its prosecution strategy to the specific patterns of AULAKH, CHARANJIT. The involvement of 1 distinct art unit further suggests that the company's current patent applications are closely related in subject matter. This narrow scope reduces the complexity of managing different examiner expectations across the USPTO.
With 1 pending office action, the portfolio is in a state of focused activity. The busiest examiner pending count of 1 reflects that the entire pending workload is concentrated under a single individual. This structure allows for a consistent approach to patent office communications, as there are no competing examiner requirements to balance within the current Biotechnology & Pharmaceuticals filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036867 | PYRAZOLO DERIVATIVES AS HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS FOR USE AS ANTIVIRALS | AULAKH, CHARANJIT | 28d overdue |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18036867 | PYRAZOLO DERIVATIVES AS HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS FOR USE AS ANTIVIRALS | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | 28d overdue | Pending | May 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial